Antimicrobial resistance is a growing worldwide problem. Urinary tract infection (UTI) is not an exception – according to European data, resistant Escherichia coli strains annually account to 32.500 cases with 5.100 deaths and 358.000 hospitalization days.
Therefore, it is crucial to regularly update the bacterial flora spectrum data and the efficacy of the recommended empiric treatment to make timely and appropriate amendments where necessary. n Latvia, the novel nitrofuran derivate (NFD) is used as a standard empiric first-choice treatment for UTI. NFDs are well-reputed as effective in low concentrations and against resistant bacteria; resistance against NFDs develops slowly and never reaches high degree; NFDs have wide activity range and are commonly used in treating urinary tract infections (UTI) both in adults and children.
First NFD were synthesized more than 60 years ago and were effectively used for treating UTI since then. However, those have side-effects, including frequent gastrointestinal disturbances, which effectively reduced NFD use especially in pediatrics.